The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Rapid Emergence of Protease Inhibitor Resistance in Hepatitis C Virus
Open accessAbstract
Computational modeling suggests that the rapid emergence of resistance to drugs against hepatitis C virus is a result of preexisting resistant virus and potent suppression of wild-type virus.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection
Fried, M. W., Shiffman, M. L., Reddy, K. R., Smith, C., Marinos, G., Gonçales, F. L., Häussinger, D., Diago, M., Carosi, G., Dhumeaux, D., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020047 · Cited by 6,389
Manns, M. P., McHutchison, J. G., Gordon, S. C., Rustgi, V. K., Shiffman, M., Reindollar, R., Goodman, Z. D., Koury, K., Ling, M.-H., & Albrecht, J. K. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06102-5 · Cited by 6,029
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance
Ge, D., Fellay, J., Thompson, A. J., Simon, J. S., Shianna, K. V., Urban, T. J., Heinzen, E. L., Qiu, P., Bertelsen, A. H., Muir, A. J., et al. (2009) · Nature · doi:10.1038/nature08309 · Cited by 3,514
Genetic variation in IL28B and spontaneous clearance of hepatitis C virus
Thomas, D. L., Thio, C. L., Martin, M. P., Qi, Y., Ge, D., O’hUigin, C., Kidd, J., Kidd, K., Khakoo, S. I., Alexander, G., et al. (2009) · Nature · doi:10.1038/nature08463 · Cited by 2,150
Finzi, D., Blankson, J., Siliciano, J. D., Margolick, J. B., Chadwick, K., Pierson, T., Smith, K., Lisziewicz, J., Lori, F., Flexner, C., et al. (1999) · Nature Medicine · doi:10.1038/8394 · Cited by 2,119
Hepatitis C Viral Dynamics in Vivo and the Antiviral Efficacy of Interferon-α Therapy
Neumann, A. U., Lam, N. P., Dahari, H., Gretch, D. R., Wiley, T. E., Layden, T. J., & Perelson, A. S. (1998) · Science · doi:10.1126/science.282.5386.103 · Cited by 2,113
Self-citationDecay characteristics of HIV-1-infected compartments during combination therapy
Perelson, A. S., Essunger, P., Cao, Y., Vesanen, M., Hurley, A., Saksela, K., Markowitz, M., & Ho, D. D. (1997) · Nature · doi:10.1038/387188a0 · Cited by 1,880
Self-citationA One-Year Trial of Lamivudine for Chronic Hepatitis B
Lai, C.-L., Chien, R.-N., Leung, N. W. Y., Chang, T.-T., Guan, R., Tai, D.-I., Ng, K.-Y., Wu, P.-C., Dent, J. C., Barber, J., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807093390201 · Cited by 1,754
Rates of evolutionary change in viruses: patterns and determinants
Duffy, S., Shackelton, L. A., & Holmes, E. C. (2008) · Nature Reviews Genetics · doi:10.1038/nrg2323 · Cited by 1,551
Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 Infection
McHutchison, J. G., Everson, G. T., Gordon, S. C., Jacobson, I. M., Sulkowski, M., Kauffman, R., McNair, L., Alam, J., & Muir, A. J. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0806104 · Cited by 1,089
Viral dynamics in hepatitis B virus infection.
Nowak, M. A., Bonhoeffer, S., Hill, A. M., Boehme, R., Thomas, H. C., & McDade, H. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.9.4398 · Cited by 1,045
Telaprevir and Peginterferon with or without Ribavirin for Chronic HCV Infection
Hézode, C., Forestier, N., Dusheiko, G., Ferenci, P., Pol, S., Goeser, T., Bronowicki, J.-P., Bourlière, M., Gharakhanian, S., Bengtsson, L., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0807650 · Cited by 1,025
An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus
Lamarre, D., Anderson, P. C., Bailey, M., Beaulieu, P., Bolger, G., Bonneau, P., Bös, M., Cameron, D. R., Cartier, M., Cordingley, M. G., et al. (2003) · Nature · doi:10.1038/nature02099 · Cited by 917
Unravelling hepatitis C virus replication from genome to function
Lindenbach, B. D., & Rice, C. M. (2005) · Nature · doi:10.1038/nature04077 · Cited by 820
Quantifying Residual HIV-1 Replication in Patients Receiving Combination Antiretroviral Therapy
Zhang, L., Ramratnam, B., Tenner-Racz, K., He, Y., Vesanen, M., Lewin, S., Talal, A., Racz, P., Perelson, A. S., Korber, B. T., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199905273402101 · Cited by 807
Self-citationSarrazin, C., Kieffer, T. L., Bartels, D., Hanzelka, B., Müh, U., Welker, M., Wincheringer, D., Zhou, Y., Chu, H., Lin, C., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.02.037 · Cited by 616
Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy
Richman, D. D., Havlir, D., Corbeil, J., Looney, D., Ignacio, C., Spector, S. A., Sullivan, J., Cheeseman, S., Barringer, K., & Pauletti, D. (1994) · Journal of Virology · doi:10.1128/jvi.68.3.1660-1666.1994 · Cited by 576
Schuurman, R., Nijhuis, M., van Leeuwen, R., Schipper, P., de Jong, D., Collis, P., Danner, S. A., Mulder, J., Loveday, C., Christopherson, C., et al. (1995) · Journal of Infectious Diseases · doi:10.1093/infdis/171.6.1411 · Cited by 503
Ramratnam, B., Bonhoeffer, S., Binley, J., Hurley, A., Zhang, L., Mittler, J. E., Markowitz, M., Moore, J. P., Perelson, A. S., & Ho, D. D. (1999) · The Lancet · doi:10.1016/s0140-6736(99)02035-8 · Cited by 481
Self-citationChallenges and successes in developing new therapies for hepatitis C
De Francesco, R., & Migliaccio, G. (2005) · Nature · doi:10.1038/nature04080 · Cited by 411
Reesink, H. W., Zeuzem, S., Weegink, C. J., Forestier, N., van Vliet, A., van de Wetering de Rooij, J., McNair, L., Purdy, S., Kauffman, R., Alam, J., et al. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.07.013 · Cited by 401
Modelling how ribavirin improves interferon response rates in hepatitis C virus infection
Dixit, N. M., Layden-Almer, J. E., Layden, T. J., & Perelson, A. S. (2004) · Nature · doi:10.1038/nature03153 · Cited by 369
Self-citationKuntzen, T., Timm, J., Berical, A., Lennon, N., Berlin, A. M., Young, S. K., Lee, B., Heckerman, D., Carlson, J., Reyor, L. L., et al. (2008) · Hepatology · doi:10.1002/hep.22549 · Cited by 349
The Hepatitis C Virus Life Cycle as a Target for New Antiviral Therapies
Pawlotsky, J., Chevaliez, S., & McHutchison, J. G. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.116 · Cited by 325
Susser, S., Welsch, C., Wang, Y., Zettler, M., Domingues, F. S., Karey, U., Hughes, E., Ralston, R., Tong, X., Herrmann, E., et al. (2009) · Hepatology · doi:10.1002/hep.23192 · Cited by 318
Sarrazin, C., Rouzier, R., Wagner, F., Forestier, N., Larrey, D., Gupta, S. K., Hussain, M., Shah, A., Cutler, D., Zhang, J., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.01.041 · Cited by 310
The way forward in HCV treatment — finding the right path
Manns, M. P., Foster, G. R., Rockstroh, J. K., Zeuzem, S., Zoulim, F., & Houghton, M. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2411 · Cited by 278
Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy
Tsiang, M., Rooney, J. F., Toole, J. J., & Gibbs, C. S. (1999) · Hepatology · doi:10.1002/hep.510290626 · Cited by 242
MacDONALD, R. A. (1961) · Archives of Internal Medicine · doi:10.1001/archinte.1961.03620030023003 · Cited by 230
Lin, K., Perni, R. B., Kwong, A. D., & Lin, C. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.5.1813-1822.2006 · Cited by 200
Havlir, D. V., Eastman, S., Gamst, A., & Richman, D. D. (1996) · Journal of Virology · doi:10.1128/jvi.70.11.7894-7899.1996 · Cited by 191
Visualizing Hepatitis C Virus Infections in Human Liver by Two-Photon Microscopy
Liang, Y., Shilagard, T., Xiao, S., Snyder, N., Lau, D., Cicalese, L., Weiss, H., Vargas, G., & Lemon, S. M. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.07.050 · Cited by 171
Zakim and Boyer's Hepatology: A Textbook of Liver Disease
BOYER, T. D., Manns, M. P., Sanyal, A. J., & Zakim, D. (2016) · Cited by 168
McCown, M. F., Rajyaguru, S., Le Pogam, S., Ali, S., Jiang, W.-R., Kang, H., Symons, J., Cammack, N., & Najera, I. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01317-07 · Cited by 164
The frequency of resistant mutant virus before antiviral therapy
Ribeiro, R. M., Bonhoeffer, S., & Nowak, M. A. (1998) · AIDS · doi:10.1097/00002030-199805000-00006 · Cited by 161
Self-citationEffect of Ribavirin on the Mutation Rate and Spectrum of Hepatitis C Virus In Vivo
Cuevas, J. M., Gónzález‐Candelas, F., Moyá, A., & Sanjuán, R. (2009) · Journal of Virology · doi:10.1128/jvi.00201-09 · Cited by 152
Hepatoimmunology: A perspective
Mackay, I. R. (2002) · Immunology and Cell Biology · doi:10.1046/j.1440-1711.2002.01063.x · Cited by 131
Antiviral resistance and specifically targeted therapy for HCV (STAT‐C)
Thompson, A. J. V., & McHutchison, J. G. (2009) · Journal of Viral Hepatitis · doi:10.1111/j.1365-2893.2009.01124.x · Cited by 108
Phenotypic Characterization of Resistant Val36Variants of Hepatitis C Virus NS3-4A Serine Protease
Zhou, Y., Bartels, D. J., Hanzelka, B. L., Müh, U., Wei, Y., Chu, H., Tigges, A. M., Brennan, D. L., Rao, B. G., Swenson, L. L., et al. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00863-07 · Cited by 94
The culture of designing hepato-biliary randomised trials
Gluud, C. N. (2006) · Journal of Hepatology · doi:10.1016/j.jhep.2005.12.006 · Cited by 79
Bélanger, M., Desjardins, P., Chatauret, N., Rose, C. F., & Butterworth, R. F. (2005) · Journal of Hepatology · doi:10.1016/j.jhep.2004.12.029 · Cited by 40
Cited by
Persistent HIV-1 replication maintains the tissue reservoir during therapy
Lorenzo-Redondo, R., Fryer, H. R., Bedford, T., Kim, E.-Y., Archer, J., Kosakovsky Pond, S. L., Chung, Y.-S., Penugonda, S., Chipman, J. G., Fletcher, C. V., et al. (2016) · Nature · doi:10.1038/nature16933 · Cited by 627
The importance of resistance to direct antiviral drugs in HCV infection in clinical practice
Sarrazin, C. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.09.011 · Cited by 423
Borgia, S. M., Hedskog, C., Parhy, B., Hyland, R. H., Stamm, L. M., Brainard, D. M., Subramanian, M. G., McHutchison, J. G., Mo, H., Svarovskaia, E., et al. (2018) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiy401 · Cited by 312
Hepatitis C virus resistance to protease inhibitors
Halfon, P., & Locarnini, S. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2011.01.011 · Cited by 305
Antiviral strategies in hepatitis C virus infection
Sarrazin, C., Hézode, C., Zeuzem, S., & Pawlotsky, J.-M. (2012) · Journal of Hepatology · doi:10.1016/s0168-8278(12)60010-5 · Cited by 283
Metadata
- Authors
- Rong, L., Dahari, H., Ribeiro, R. M., & Perelson, A. S.
- Venue
- Science Translational Medicine
- Published
- 2010-05-05
- Volume
- 2
- Issue
- 30
- Pages
- 30ra32-30ra32
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W2164211111
- Cited by
- 355
- References
- 41
- FWCI
- 29.92
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.